OncLive TV

Neal D. Shore, MD, FACS, medical director of the Carolina Urologic Research Center, discusses the clinical utility of piflufolastat F 18 in identifying suspected metastasis or recurrence of prostate cancer.

Jennifer Litton, MD, discusses the safety of talazoparib (Talzenna) in the neoadjuvant treatment of patients with germline BRCA1/2-positive, early-stage HER2-negative breast cancer.

Scott Tagawa, MD, MS, FACP, discuss the integration of targeted agents in prostate cancer.

Riad Salem, MD, discusses the history of TheraSphere™ Yttrium-90 in metastatic colorectal cancer.

Hans Hammers, MD, PhD,discusses the safety profile of lenvatinib in combination with pembrolizumab in renal cell carcinoma.

Pauline Funchain, MD, discusses the rationale for the phase 3 SWOG S1404 trial in high-risk resected melanoma.

Julie M. Vose, MD, MBA, discusses the potential utility of CAR T-cell therapy across the non-Hodgkin lymphoma paradigm.

Jonathan Spicer, MD, PhD, discusses the efficacy observed with neoadjuvant nivolumab plus platinum-doublet chemotherapy in patients with resectable non–small cell lung cancer.

Lyndsay Willmott, MD, discusses the expanding role for genomic testing in ovarian cancer.

Michael J. Morris, MD, discusses findings from the phase 2 TheraP study, and how they led to the development of the phase 3 VISION trial in metastatic castration-resistant prostate cancer.

Earle Burgess, MD, discusses the integration of PARP inhibitors in advanced prostate cancer.

Bradley J. Monk, MD, FACS, FACOG, discusses the utility of PARP inhibitors as frontline maintenance therapy in ovarian cancer.

Rachel N. Grisham, MD, discusses rationale for evaluating binimetinib as a treatment option for patients with low-grade serous ovarian cancer.

Anita Kumar, MD, discusses future directions with pirtobrutinib in mantle cell lymphoma.

Wassim Abida, MD, PhD, discusses data from the phase 3 , PROfound trial in patients with metastatic castration-resistant prostate cancer.

Michael J. Morris, MD, discusses the efficacy of Lutetium 177 PSMA-617 as a treatment for patients with metastatic castration-resistant prostate cancer.

Jacob G. Scott, MD, DPhil, discusses the rationale to evaluate genomic-adjusted radiation dose–based radiotherapy dosing in oncology.

Krina K. Patel, MD, MSc, discusses the potential utility of elranatamab in multiple myeloma.

Stephen M. Ansell, MD, PhD, discusses the utility of non–CAR T-cell therapy options in non-Hodgkin lymphoma.

Anita Kumar, MD, discusses efforts made to address areas of unmet need in mantle cell lymphoma.

Martine Extermann, MD, PhD, shares advice for selecting among the CDK4/6 available for the treatment of patients with hormone receptor–positive breast cancer.

Christine Sam, MD, discusses strategies for sequencing tucatinib and fam-trastuzumab deruxtecan-nxki in the treatment of patients with HER2-positive breast cancer.

Lisa A. Carey, MD, FASCO, discusses the updated results of the phase 3 PALOMA-3 trial in hormone receptor–positive, HER2-positive breast cancer.

David M. O'Malley, MD discusses the utility of chemoimmunotherapy in ovarian cancer.

Hung Khong, MD, underscores the importance of testing for BRCA mutations in patients with breast cancer. 

Peter G. Miller, MD, PhD, discusses the characteristics of clonal hematopoiesis.

Wassim Abida, MD, PhD, discusses the limitations of PARP inhibitors in prostate cancer.

Peter Martin, MD, discusses the importance of designing clinical trials for real-world utility in mantle cell lymphoma.

Anita Kumar, MD, discusses navigating CAR T-cell therapy–related toxicities in mantle cell lymphoma.

Alexey V. Danilov, MD, PhD, discusses the efficacy seen in the ongoing phase 1b study examining the combination of zandelisib and zanubrutinib in patients with relapsed/refractory B-cell malignancies.